 |
|
Hypopigmentation Associated With an Adenovirus-Mediated gp100/MART-1–Transduced Dendritic Cell Vaccine for Metastatic Melanoma
Hensin Tsao, MD, PhD;
Peri Millman, MD;
Gerald P. Linette, MD, PhD;
F. Stephen Hodi, MD;
Arthur J. Sober, MD;
Mark A. Goldberg, MD;
Frank G. Haluska, MD, PhD
Arch Dermatol. 2002;138:799-802.
Background Reports of vitiligo associated with metastases and rare cases of spontaneous
regression of disease have fueled enthusiasm for immunologic approaches to
the treatment of advanced melanoma. More recent strategies have focused on
using antigen-presenting dendritic cells as vaccines.
Observations We observed 3 cases of leukoderma associated with a novel adenovirus-mediated
gp100/MART-1–transduced dendritic cell (MART indicates melanoma antigen
recognized by T cells). All 3 patients had advanced metastatic melanoma. Despite
the development of this leukodermic response, all patients experienced disease
progression while under treatment.
Conclusion We provide the initial evidence for effective induction of a leukodermic
response with a gp100/MART-1–transduced dendritic cell vaccine.
From the Department of Dermatology (Drs Tsao and Sober), the Wellman
Laboratories of Photomedicine (Dr Tsao), the Melanoma Center (Drs Tsao, Sober,
and Haluska), and the Division of Oncology (Dr Haluska), Massachusetts General
Hospital, and the Department of Adult Oncology, Dana Farber Cancer Institute
(Dr Hodi), Boston, Mass; the Department of Pediatrics, Albert Einstein College
of Medicine, New York (Bronx), NY (Dr Millman); the Department of Medicine,
Washington University, St Louis, Mo (Dr Linette); and Genzyme Molecular Oncology,
Framingham, Mass (Dr Goldberg). Dr Goldberg is an employee of, and owns stock
in, Genzyme Corporation Pharmaceuticals, Framingham.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients
Luiten et al.
JCO 2005;23:8978-8991.
ABSTRACT
| FULL TEXT
Management of Cutaneous Melanoma
Tsao et al.
NEJM 2004;351:998-1012.
FULL TEXT
|
